Fueling St. Louis’ Innovation Economy
BioGenerator, our startup arm, has reached a remarkable milestone: $50 million invested in St. Louis bioscience startups. Over the past two decades, those BioGenerator investments have helped launch more than 130 companies, attracted nearly $3 billion in follow-on capital, and created thousands of high-quality jobs across the region.
This milestone isn’t just about the number. It’s about the impact.
“The $50 million threshold in itself is not what’s important. Anyone can send money out the door,” said Donn Rubin, CEO and Founding President of BioSTL. “What’s important is how smartly deployed that $50 million has been to drive impact in the St. Louis region.”
That “smart deployment” has been the secret behind BioGenerator’s long-term success. Since 2004, this nonprofit venture capital in St. Louis has invested strategically, identifying high-potential opportunities, guiding founders through critical early stages, and leveraging every dollar to attract outside capital and talent to St. Louis.
Smart Investments That Build Companies and Communities
BioGenerator’s portfolio includes 130+ companies across human health, plant science, and agtech. Beyond funding, the BioSTL startup ecosystem provides hands-on support from business leadership and fundraising expertise to lab and office space.
That ecosystem-first approach has turned early-stage ideas into industry leaders:
- Wugen, born out of Washington University research and nurtured by BioGenerator's early investment and lab, is pioneering breakthrough cancer cell therapies and has raised hundreds of millions in follow-on capital.
- CoverCress, supported by BioGenerator from day one, has transformed field pennycress into a renewable oilseed crop, now backed by Chevron, Bayer, and Bunge — while keeping operations in St. Louis.
- Confluence Life Sciences, another BioGenerator Labs success, developed novel small-molecule therapies and grew into a major acquisition by Aclaris Therapeutics, further expanding the region’s bioscience footprint.
These success stories demonstrate the compounding effect of early-stage biotech investing; every dollar put in sparks local hiring, research, and economic growth.
Where Does BioGenerator’s Investment Money Come From?
Unlike traditional venture firms, BioGenerator is a nonprofit with a charitable mission: to grow St. Louis’ bioscience economy.
Its investment dollars come from generous donors — individuals, foundations, and organizations who believe in St. Louis’ potential as a global innovation hub. Since 2004, BioGenerator has invested about $3 million per year (closer to $3.5 million in the past decade), all thanks to donor support or returns on prior investments..
Every return generated from BioGenerator’s portfolio is reinvested directly back into the mission, fueling even more startups, creating new jobs, and ensuring the region’s innovation engine keeps running strong.
This unique model demonstrates the real power of impact investing, where each dollar works for St. Louis by attracting global investors, creating opportunity, and building a sustainable cycle of innovation.
A Vision for St. Louis’ Innovation Future
By bridging the funding gap for early-stage bioscience companies, BioGenerator has helped position St. Louis as a nationally recognized hub for entrepreneurship, research, and discovery.
“This milestone reflects the vision of our founders and the trust of the entrepreneurs who choose to start their companies here in St. Louis,” said Jim McCarter, Senior Managing Director of BioGenerator. “Our role is to take high-risk, early bets that others won’t — and time and again, those bets have paid off.”
With $50 million deployed, billions in follow-on investment, and a growing network of success stories, BioGenerator investments continue to prove that strategic early-stage biotech investing can power a St. Louis innovation economy.
